Clinical Trials
69 trialsMK-3475-01E
Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
MASTER-2
University of Alabama at Birmingham
VIWA-1
University of Ulm
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
ADGP
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADTD
Second Affiliated Hospital, School of Medicine, Zhejiang University
ADDC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
BOREALIS
Canadian Myeloma Research Group
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
MOMENTUM
C4 Therapeutics, Inc.
Iber-KDd
University of Miami
RESPIRE-ILD
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
PILDI
Institute of Oncology Ljubljana
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
SELVEDge
University of Miami
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Karyopharm Therapeutics Inc
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
VICD
Medical College of Wisconsin
ISABELA
Massachusetts General Hospital
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Roswell Park Cancer Institute
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
FIL_DALYA
Fondazione Italiana Linfomi - ETS
HD10/DSMMXX
University of Heidelberg Medical Center
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Institute of Hematology & Blood Diseases Hospital, China
UltraFrailMM
University of Utah
BrECADD
University of Miami
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
University of Miami
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
University of California, Davis